- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04555785
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor (Will-Plate)
Study Overview
Detailed Description
Von Willebrand Factor (vWF) is a key protein mediating platelet adhesion on the surface of damaged endothelia, initiating platelet-platelet aggregation and supporting platelet activation. It plays also an important role in protecting FVIII from early activation and clearance . The product's included coagulation factor VIII acts in in the activated form like the regular factor VIIIa. It takes part in the coagulation amplification by activating factor X to Xa together with factor IVa. Activation of factor X results in generating thrombin out of prothrombin. Wilate® is approved in Switzerland for prophylaxis and treatment of bleeding in patients suffering from von Willebrand disease and Haemophilia A.
VWF is produced by the endothelial cells as a heterogeneous mixture of low and high molecular weight units. VWF is a ligand for receptors on the platelet surface and endothelial cells (GP1b-V-IX, αIIbβ3, αvβ3) mediating adhesion of platelets to each other or to the endothelium. Initial platelet adhesion is a crucial step in haemostatic functioning. Loss of platelets, vWF or blocking of these integrins due to the wide use of platelet aggregation inhibitors can cause bleeding. In case of severe blood loss, these conditions often result in mass transfusion.
There is suggestive evidence from an in-vitro flow chamber model and from treatment of patients with severe vWF deficiency that increasing the concentration of vWF onto normal or high normal levels can enhance platelet adhesion independent from platelet count. This might translate into a better haemostatic effect of administered platelet concentrates in the bleeding patient and less need for transfusion of blood products (platelet concentrates), especially in clinical conditions with a high probability of low platelet count and low vWF activities (e.g., heart surgery with extracorporeal circulation, ECMO).
To the best of our knowledge, no trial exists that investigated the effect of platelet transfusion in combination with the administration of balanced vWF in severe blood loss. The investigators hypothesize that simultaneous transfusion of platelets and balanced (1:1 vWF and FVIII) vWF compared to placebo reduces the overall need of transfusion of blood products.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Martin Siegemund, Prof. Dr. MD
- Phone Number: 0041613286414
- Email: martin.siegemund@usb.ch
Study Contact Backup
- Name: Andrea Blum, med. pract.
- Phone Number: 0041796903886
- Email: andrea.blum@hotmail.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- University Hospital Basel
-
Contact:
- Martin Siegemund, MD
- Phone Number: +41613286414
- Email: martin.siegemund@usb.ch
-
Contact:
- Alexa Hollinger, MD
- Phone Number: +41613286508
- Email: alexa.hollinger@usb.ch
-
Sub-Investigator:
- Lukas Gantner, MD
-
Sub-Investigator:
- Katrin Ledergerber, MD candidate
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Admission to intensive care unit
- Patients needing platelet transfusion during or after surgery with or without prior treatment with single or dual antiplatelet agents (ASS, Prasugrel, Clopidogrel, Ticagrelor)
- Consent by the patient or a family member in addition to the consent of an independent ICU physician
Exclusion Criteria:
- Patients receiving Factor VIII concentrate before inclusion of the study (Haemate ®)
- Women who are pregnant or breastfeeding
- Participation in another study with an investigational drug within the 30 days preceding and during the present study
- Overt Disseminated Intravascular Coagulation (DIC)
- Heparin-induced Thrombocytopenia (HIT)
- Thrombotic Thrombocytopenic Purpura (TTP) or Haemolytic uremic Syndrome (HUS)
- Idiopathic thrombocytopenic purpura (ITP)
- Sepsis
- Patients with known inherited thrombocytopathies
- Patients with known von Willebrand disease or Haemophilia A
- Patients with known hemato-oncological diseases
- Previous enrolment into the current study
- Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Platelet transfusion with Wilate ®
|
Wilate ® will be given with platelets in cases of severe bleeding.
Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential.
It is extracted from plasma, freeze-dried and virus-inactivated.
|
Placebo Comparator: Platelet transfusion with Placebo
|
Empty placebo will be given with platelets in cases of severe bleeding.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of blood products
Time Frame: 48 hours
|
Number of blood products (fresh frozen plasma (FFP), red blood cells (RBC)) according to groups.
|
48 hours
|
Collaborators and Investigators
Investigators
- Study Chair: Martin Siegemund, Prof. Dr. MD, University Hospital, Basel, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2020-02106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding
-
Ethicon, Inc.Guangzhou Bioseal Biotechnology Co., Ltd.Completed
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Ethicon, Inc.CompletedHemorrhage | Soft Tissue Bleeding | Hepatic Parenchyma BleedingUnited Kingdom, Belgium
-
Hyloris DevelopmentsRecruitingBleeding From Teeth | Bleeding ProphylaxisSpain, United States, Belgium, Croatia, Hungary, Romania
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Wake Forest University Health SciencesCompletedBleeding ComplicationUnited States
-
Chinese University of Hong KongCompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active BleedingChina
-
Chinese University of Hong KongBeijing Friendship Hospital; The First Affiliated Hospital of Soochow University and other collaboratorsCompletedAcute Upper Gastrointestinal Bleeding | Tumor BleedingHong Kong, China, Australia
-
Women and Infants Hospital of Rhode IslandActive, not recruitingAbnormal Uterine Bleeding | Abnormal Uterine Bleeding, Ovulatory Dysfunction | Abnormal Uterine Bleeding, Endometrial Hemostatic DysfunctionUnited States
Clinical Trials on Wilate
-
OctapharmaCompletedSevere Hemophilia ARussian Federation, Ukraine
-
University of California, DavisTerminatedHemophilia A | Hemophilia A With InhibitorUnited States
-
OctapharmaActive, not recruitingVon Willebrand DiseaseUnited States, Moldova, Republic of, Czechia, Germany, North Macedonia, Russian Federation, Ukraine
-
OctapharmaCompletedVon Willebrand DiseaseUnited States, Canada, Sweden, Spain, Uruguay, United Kingdom, Portugal, Argentina, Czechia, Germany
-
OctapharmaTerminated
-
OctapharmaCompletedVon Willebrand DiseasesLebanon, Croatia, United States, Belarus, Bulgaria, Hungary, Russian Federation, Ukraine
-
OctapharmaCompletedSevere Hemophilia ABulgaria, Poland, Hungary, Romania, Russian Federation
-
Unity Health TorontoNot yet recruiting
-
Emory UniversityOctapharmaRecruitingHemophilia AUnited States, Germany
-
City of Hope Medical CenterCSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaboratorsCompletedSevere Hemophilia AUnited States